UBS increased its price target for Berkshire Hathaway shares, citing an 8% discount to intrinsic value and stronger second-quarter earnings estimates. The bank highlighted Berkshire's $8.5 billion stock buybacks, improved results from BNSF railroad, and lower insurance catastrophe losses as key factors. UBS also raised 2026 and 2027 earnings forecasts, driven by higher buybacks and solid performance across Berkshire's energy and manufacturing units. The outlook includes some pressure on GEICO's underwriting margins but growth in other segments is expected to continue.
Halper Sadeh LLC is investigating whether the sales and mergers involving Utz Brands, BioLife Solutions, and Northrim BanCorp provide fair financial terms to their shareholders. The firm suspects insiders might gain benefits not available to ordinary...
Mesoblast announced $36 million in net revenue for Q4 and $115 million for the first full year following FDA approval of its Ryoncil therapy, used to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The company is expa...
Fortuna Mining Corp. has approved a $109 million expansion of its Séguéla Gold Mine in Côte d’Ivoire, increasing processing capacity by 30% from 1.75 to 2.3 million tonnes per annum and improving gold recovery to 94.5%. This expansion includes upgrad...
BeOne Medicines is evolving from relying on its BRUKINSA drug to becoming an integrated hematology and oncology company with multiple growth drivers. In Q1 2026, the company reported a 35.5% increase in revenue, expanding profit margins, and rising p...
Quantum BioPharma has closed a debt settlement by issuing 30,948 Class B subordinate voting shares worth CAD$123,487.43 to its creditors. The shares were priced at CAD$3.99 each, based on the previous trading day's closing price on the Canadian Secur...
